These first proof-of-concept experiments demonstrate that the insertion of the EF1α promoter with the FVIII gene in the human FVIII locus is a suitable strategy for the restoration of FVIII expression, and provides a valuable and universal tool for future ex vivo cell therapy for patients with hemophilia A. This evidence concerns the gene F8 and hemophilia A.